Performance report to the President and Congress for the Biosimilar User Fee Act.

Format:

Government document

Journal/Periodical

Author/Creator:

United States. Food and Drug Administration, author.

Contributor:

Center for Biologics Evaluation and Research (U.S.)

Center for Drug Evaluation and Research (U.S.)

Language:

English

Subjects (All):

United States. Food and Drug Administration Safety and Innovation Act--Periodicals.

United States.

United States. Food and Drug Administration--Rules and practice--Periodicals.

United States. Food and Drug Administration--Finance--Periodicals.

Biosimilars--United States--Testing--Periodicals.

Biosimilars.

Drug approval--United States--Costs--Periodicals.

Drug approval.

Biologicals--Law and legislation--Periodicals.

Biologicals.

User charges--United States--Periodicals.

User charges.

Physical Description:

1 online resource (volumes)

Annual

Began with: FY 2013; ceased with: FY 2014.

Other Title:

BsUFA performance report

Continued By:

United States. Food and Drug Administration. Performance report to Congress for the Biosimilar User Fee Act

Place of Publication:

Silver Spring, Maryland : Food and Drug Administration, Department of Health and Human Services, 2013-2014.

Notes:

Reports include data tables.

In scope of the U.S. Government Publishing Office Cataloging and Indexing Program (C&I) and Federal Depository Library Program (FDLP).

Prepared in collaboration with: Center for Biologics Evaluation and Research (CBER), 2013-2014; with: Center for Drug Evaluation and Research (CDER), 2013-2014.

FY 2013; title from PDF cover (FDA, viewed July 16, 2025).

FY 2014 (FDA, viewed July 16, 2025).

OCLC:

1528110365